Extracellular Vesicles: A Novel Tool Facilitating Personalized Medicine and Pharmacogenomics in Oncology.
biomarker
cancer
extracellular vesicle
liquid biopsy
personalized medicine
pharmacogenomics
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
02
2021
accepted:
19
04
2021
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
18
5
2021
Statut:
epublish
Résumé
Biomarkers that can guide cancer therapy based on patients' individual cancer molecular signature can enable a more effective treatment with fewer adverse events. Data on actionable somatic mutations and germline genetic variants, studied by personalized medicine and pharmacogenomics, can be obtained from tumor tissue or blood samples. As tissue biopsy cannot reflect the heterogeneity of the tumor or its temporal changes, liquid biopsy is a promising alternative approach. In recent years, extracellular vesicles (EVs) have emerged as a potential source of biomarkers in liquid biopsy. EVs are a heterogeneous population of membrane bound particles, which are released from all cells and accumulate into body fluids. They contain various proteins, lipids, nucleic acids (miRNA, mRNA, and DNA) and metabolites. In cancer, EV biomolecular composition and concentration are changed. Tumor EVs can promote the remodeling of the tumor microenvironment and pre-metastatic niche formation, and contribute to transfer of oncogenic potential or drug resistance during chemotherapy. This makes them a promising source of minimally invasive biomarkers. A limited number of clinical studies investigated EVs to monitor cancer progression, tumor evolution or drug resistance and several putative EV-bound protein and RNA biomarkers were identified. This review is focused on EVs as novel biomarker source for personalized medicine and pharmacogenomics in oncology. As several pharmacogenes and genes associated with targeted therapy, chemotherapy or hormonal therapy were already detected in EVs, they might be used for fine-tuning personalized cancer treatment.
Identifiants
pubmed: 33995103
doi: 10.3389/fphar.2021.671298
pii: 671298
pmc: PMC8120271
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
671298Informations de copyright
Copyright © 2021 Goričar, Dolžan and Lenassi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur Rev Med Pharmacol Sci. 2017 Jun;21(11):2650-2658
pubmed: 28678319
PLoS One. 2017 Apr 3;12(4):e0175050
pubmed: 28369094
Proteomics. 2012 Jan;12(2):329-38
pubmed: 22106071
Nat Cell Biol. 2008 Dec;10(12):1470-6
pubmed: 19011622
Sci Rep. 2018 Oct 2;8(1):14707
pubmed: 30279572
Drug Resist Updat. 2019 Dec;47:100647
pubmed: 31704541
Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737):
pubmed: 29158318
Proteomics. 2013 Jul;13(14):2125-34
pubmed: 23585444
J Extracell Vesicles. 2018 Aug 07;7(1):1505403
pubmed: 30108686
Cancer Manag Res. 2017 Dec 07;9:801-811
pubmed: 29263703
Nat Commun. 2018 Jul 9;9(1):2658
pubmed: 29985392
Cancer J. 2018 Mar/Apr;24(2):65-69
pubmed: 29601332
Nucleic Acids Res. 2019 Jan 8;47(D1):D516-D519
pubmed: 30395310
Clin Pharmacokinet. 2018 Oct;57(10):1229-1254
pubmed: 29520731
J Proteomics. 2013 Mar 27;80:171-82
pubmed: 23333927
Eur J Pharmacol. 2018 Sep 5;834:188-196
pubmed: 30031797
Biochim Biophys Acta. 2006 Aug;1766(1):120-39
pubmed: 16889899
Public Health Genomics. 2010;13(5):284-91
pubmed: 19815999
Front Oncol. 2019 Sep 25;9:931
pubmed: 31608233
Mol Cancer. 2017 Jul 25;16(1):132
pubmed: 28743280
J Biol Chem. 2015 Oct 2;290(40):24534-46
pubmed: 26272609
Nat Rev Cancer. 2015 Dec;15(12):747-56
pubmed: 26536825
Ann Oncol. 2018 Mar 1;29(3):700-706
pubmed: 29216356
Breast Cancer Res. 2020 Oct 6;22(1):105
pubmed: 33023655
Cancers (Basel). 2019 May 16;11(5):
pubmed: 31100836
Precis Clin Med. 2018 Jun;1(1):29-48
pubmed: 30687561
Proteomics. 2013 May;13(10-11):1672-86
pubmed: 23585443
PLoS One. 2019 May 2;14(5):e0215990
pubmed: 31048929
Mol Cell Proteomics. 2010 Jun;9(6):1324-38
pubmed: 20224111
Breast Cancer Res. 2019 Feb 6;21(1):21
pubmed: 30728048
Pharmacogenomics. 2011 Mar;12(3):433-42
pubmed: 21449681
Transl Lung Cancer Res. 2019 Aug;8(4):392-400
pubmed: 31555514
Biomed Res Int. 2019 Dec 11;2019:1628029
pubmed: 31915681
Leukemia. 2014 Aug;28(8):1666-75
pubmed: 24480987
Breast J. 2019 Jul;25(4):691-695
pubmed: 31079422
Clin Cancer Res. 2016 Jan 15;22(2):395-404
pubmed: 26369630
BMC Genomics. 2009 Nov 25;10:556
pubmed: 19930720
Pharmacogenomics. 2019 May;20(7):493-502
pubmed: 31124410
Theranostics. 2017 Aug 23;7(16):3824-3841
pubmed: 29109780
Oncol Lett. 2017 May;13(5):3608-3616
pubmed: 28521461
Front Pharmacol. 2020 Jan 24;10:1608
pubmed: 32038264
J Immunol. 2017 Feb 15;198(4):1649-1659
pubmed: 28069806
Pharmacogenomics. 2019 Jan;20(1):49-68
pubmed: 30520336
Biochem Biophys Res Commun. 2014 Mar 21;445(4):694-701
pubmed: 24434149
Pharmazie. 2013 Dec;68(12):969-73
pubmed: 24400444
Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):911-22
pubmed: 27249175
Pharmacogenomics J. 2013 Feb;13(1):1-11
pubmed: 23089672
J Biosci. 2019 Jun;44(2):
pubmed: 31180050
Nat Rev Clin Oncol. 2013 Aug;10(8):472-84
pubmed: 23836314
Ann Oncol. 2018 Dec 1;29(12):2379-2383
pubmed: 30339193
Nature. 2012 Jun 28;486(7404):537-40
pubmed: 22722843
Nat Med. 2012 Dec;18(12):1835-40
pubmed: 23142818
Mol Aspects Med. 2020 Apr;72:100828
pubmed: 31711714
BMC Cancer. 2017 Feb 1;17(1):92
pubmed: 28143451
Clin Transl Oncol. 2018 Jul;20(7):906-911
pubmed: 29143228
Sci Rep. 2019 Apr 25;9(1):6571
pubmed: 31024054
Curr Opin Oncol. 2016 Mar;28(2):130-4
pubmed: 26730486
J Leukoc Biol. 2020 Aug;108(2):601-616
pubmed: 32108378
Oncoimmunology. 2017 Aug 11;6(12):e1362530
pubmed: 29209569
Theranostics. 2018 Feb 7;8(6):1540-1557
pubmed: 29556340
Prostate. 2014 Oct;74(14):1379-90
pubmed: 25111183
Neuro Oncol. 2018 Jan 22;20(2):236-248
pubmed: 29016925
AAPS J. 2017 Nov 27;20(1):4
pubmed: 29181807
Pharmacogenomics J. 2015 Aug;15(4):372-9
pubmed: 25582575
Nat Biotechnol. 2011 Apr;29(4):341-5
pubmed: 21423189
ACS Nano. 2019 Sep 24;13(9):10499-10511
pubmed: 31469961
J Clin Oncol. 2018 Jan 10;36(2):136-143
pubmed: 29220298
Front Oncol. 2014 Oct 08;4:267
pubmed: 25340037
Nat Commun. 2017 May 16;8:15287
pubmed: 28508895
Mol Oncol. 2020 Aug 7;:
pubmed: 32767659
Clin Pharmacol Ther. 2019 Jun;105(6):1407-1420
pubmed: 30554411
Adv Drug Deliv Rev. 2020;159:308-321
pubmed: 32151658
Pharmacogenomics. 2014 Aug;15(11):1479-94
pubmed: 25303299
Ann Oncol. 2016 Apr;27(4):635-41
pubmed: 26681674
Nat Rev Mol Cell Biol. 2020 Oct;21(10):585-606
pubmed: 32457507
Cancer Sci. 2006 Jun;97(6):523-9
pubmed: 16734731
Mol Cancer. 2018 Jan 27;17(1):15
pubmed: 29374476
Nat Cell Biol. 2018 Mar;20(3):332-343
pubmed: 29459780
Expert Rev Mol Diagn. 2015;15(7):907-23
pubmed: 25948243
Trends Cancer. 2020 Sep;6(9):767-774
pubmed: 32307267
Clin Genet. 2019 Jun;95(6):643-660
pubmed: 30671931
Oncotarget. 2015 Oct 6;6(30):30357-76
pubmed: 26196085
J Extracell Vesicles. 2015 Jun 19;4:27522
pubmed: 26095380
PLoS Biol. 2012;10(12):e1001450
pubmed: 23271954
Nature. 2017 Jun 22;546(7659):498-503
pubmed: 28607485
Cells. 2020 Nov 19;9(11):
pubmed: 33228060
Clin Pharmacol Ther. 2020 May;107(5):1240-1255
pubmed: 31715018
Br J Cancer. 2014 Mar 18;110(6):1409-12
pubmed: 24548867
Pharmacogenomics. 2016 Mar;17(4):435-51
pubmed: 26894782
Nature. 2018 Aug;560(7718):382-386
pubmed: 30089911
J Pers Med. 2021 Jan 28;11(2):
pubmed: 33525618
Cell Res. 2014 Jun;24(6):766-9
pubmed: 24710597
J Biol Chem. 2014 Feb 14;289(7):3869-75
pubmed: 24398677
Cell Mol Gastroenterol Hepatol. 2018 Jan 31;5(4):627-629.e6
pubmed: 29930982
Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):1877-1886
pubmed: 32141557
Cancer Immunol Immunother. 2010 Jun;59(6):841-50
pubmed: 20043223
J Surg Oncol. 2017 Jun;115(8):932-940
pubmed: 28334432
BMC Cancer. 2018 Dec 10;18(1):1236
pubmed: 30526536
Mol Cell Proteomics. 2013 Feb;12(2):343-55
pubmed: 23161513
Oncogene. 2006 Mar 13;25(11):1679-91
pubmed: 16550168
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Carcinogenesis. 2015 Sep;36(9):1008-18
pubmed: 26054723
Int J Oncol. 2018 Sep;53(3):1013-1026
pubmed: 30015837
Ann Oncol. 2017 Apr 1;28(4):741-747
pubmed: 28104621
Mol Cancer. 2019 Dec 12;18(1):182
pubmed: 31830995
Cancers (Basel). 2019 Mar 26;11(3):
pubmed: 30917536
Cells. 2020 Jan 06;9(1):
pubmed: 31935901
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Mol Pharm. 2018 May 7;15(5):1892-1900
pubmed: 29595984
Nanomedicine. 2018 Apr;14(3):875-882
pubmed: 29288729
Cancers (Basel). 2019 Feb 21;11(2):
pubmed: 30795562
Cancers (Basel). 2019 Jun 04;11(6):
pubmed: 31167492
Mol Cancer Res. 2017 Jun;15(6):683-695
pubmed: 28202504
Proteomics. 2017 Dec;17(23-24):
pubmed: 28842968
Mol Cell Proteomics. 2018 Oct;17(10):1948-1964
pubmed: 30006486
Nat Cell Biol. 2019 Feb;21(2):190-202
pubmed: 30598531
Br J Cancer. 2018 Mar 20;118(6):820-824
pubmed: 29509748
Clin Cancer Res. 2018 Jun 15;24(12):2944-2950
pubmed: 29535126
Cancer Biol Ther. 2017 Mar 4;18(3):158-165
pubmed: 28121262
Clin Pharmacol Ther. 2012 Oct;92(4):414-7
pubmed: 22992668
Biochem Biophys Res Commun. 2018 Sep 10;503(3):1267-1272
pubmed: 30017201
Proteomics Clin Appl. 2015 Jun;9(5-6):568-73
pubmed: 25471207
Biomark Med. 2020 Apr;14(6):451-458
pubmed: 32270699
Clin Cancer Res. 2019 Jan 1;25(1):266-276
pubmed: 30287549
Int J Mol Sci. 2019 Dec 07;20(24):
pubmed: 31817878
Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):E9066-E9075
pubmed: 29073103
J Exp Med. 2019 May 6;216(5):1061-1070
pubmed: 30975894
Cancer Sci. 2017 Mar;108(3):448-454
pubmed: 28032400
Mol Oncol. 2018 Jan;12(1):3-20
pubmed: 29124875
Int J Biochem Cell Biol. 2018 Jun;99:236-256
pubmed: 29654900
EMBO J. 1997 Apr 1;16(7):1647-55
pubmed: 9130710
Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):E968-77
pubmed: 26858453
Oncotarget. 2016 Dec 27;7(52):86999-87015
pubmed: 27894104
Cancer Treat Rev. 2012 May;38(3):226-34
pubmed: 21757296
Nature. 2012 Jun 28;486(7404):532-6
pubmed: 22722830
Mol Aspects Med. 2018 Apr;60:15-26
pubmed: 29196097
Biochem Biophys Res Commun. 2014 Aug 22;451(2):295-301
pubmed: 25086355
Blood. 2015 Aug 27;126(9):1106-17
pubmed: 26100252
Br J Cancer. 2004 Jul 19;91(2):344-54
pubmed: 15213713
J Extracell Vesicles. 2019 Aug 27;8(1):1656993
pubmed: 31497265
Mol Cancer Ther. 2005 Oct;4(10):1595-604
pubmed: 16227410
Physiol Rep. 2014 Aug 19;2(8):
pubmed: 25138791
Oncogene. 2018 Jun;37(24):3183-3199
pubmed: 29540830
Cell Death Dis. 2020 Jul 27;11(7):584
pubmed: 32719324
J Am Soc Nephrol. 2009 Feb;20(2):363-79
pubmed: 19056867
Talanta. 2019 Mar 1;194:243-252
pubmed: 30609526
Oncotarget. 2015 Aug 28;6(25):21740-54
pubmed: 25844599
Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):711-6
pubmed: 24379393
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Acta Pharmacol Sin. 2017 Nov;38(11):1475-1485
pubmed: 28836580
Pharmacogenomics J. 2017 Jan;17(1):21-28
pubmed: 27503581
BMC Cancer. 2016 Sep 23;16(1):753
pubmed: 27662833
Trends Mol Med. 2014 Jul;20(7):385-93
pubmed: 24703619
J Cell Physiol. 2012 Feb;227(2):658-67
pubmed: 21465472
Nat Cell Biol. 2008 May;10(5):619-24
pubmed: 18425114
Cancer Res. 2003 Aug 1;63(15):4331-7
pubmed: 12907600
J Exp Clin Cancer Res. 2019 Jul 19;38(1):320
pubmed: 31324203
Oncoimmunology. 2015 Mar 2;4(6):e1008347
pubmed: 26155415
Mol Cancer. 2019 Mar 30;18(1):55
pubmed: 30925923
Hum Mol Genet. 2013 Dec 15;22(24):4988-5000
pubmed: 23886663
Nature. 2015 Jul 9;523(7559):177-82
pubmed: 26106858
Clin Cancer Res. 2018 Jan 1;24(1):181-188
pubmed: 29051321
Br J Clin Pharmacol. 2019 Jan;85(1):216-226
pubmed: 30340248
Cancer Cell. 2018 Jul 9;34(1):119-135.e10
pubmed: 29937354
Gene. 2017 Aug 5;623:5-14
pubmed: 28438694
J Mol Cell Biol. 2013 Aug;5(4):227-38
pubmed: 23580760
Pharmacogenet Genomics. 2014 Aug;24(8):387-96
pubmed: 25007187
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Proteomics. 2014 Jun;14(12):1472-9
pubmed: 24733759
Transl Lung Cancer Res. 2013 Jun;2(3):160-71
pubmed: 25806229
Urol Oncol. 2015 Sep;33(9):385.e15-20
pubmed: 26027763
Int J Oncol. 2018 Aug;53(2):527-538
pubmed: 29845246
Annu Rev Cell Dev Biol. 2014;30:255-89
pubmed: 25288114
Front Cardiovasc Med. 2018 Aug 22;5:113
pubmed: 30186839
Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15336-41
pubmed: 21873242
Genes Chromosomes Cancer. 2012 Apr;51(4):409-18
pubmed: 22420032
Leukemia. 2009 Sep;23(9):1643-9
pubmed: 19369960
Cancer Epidemiol. 2015 Apr;39(2):182-8
pubmed: 25592234
Mol Cancer. 2018 Oct 5;17(1):145
pubmed: 30290811
Public Health Genomics. 2017;20(2):116-125
pubmed: 28723694
J Mol Biol. 2016 Feb 22;428(4):688-692
pubmed: 26434508
Proteomics. 2019 Apr;19(8):e1800149
pubmed: 30758141
Neuro Oncol. 2019 Dec 17;21(12):1610-1611
pubmed: 31504796
Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):109-116
pubmed: 30528756
Life Sci. 2011 Aug 29;89(9-10):304-12
pubmed: 21763319
J Extracell Vesicles. 2013 Dec 23;2:
pubmed: 24371517
N Engl J Med. 2011 Oct 6;365(14):1273-83
pubmed: 21991949
Anticancer Res. 2018 Jul;38(7):3935-3942
pubmed: 29970515
Sci Rep. 2017 Feb 15;7:42339
pubmed: 28198398
Mol Ther. 2013 Jan;21(1):185-91
pubmed: 23032975
Proteomics. 2011 Jun;11(12):2459-75
pubmed: 21595033
Biochem Biophys Res Commun. 2017 Sep 23;491(3):675-680
pubmed: 28756226
Oncogene. 2020 May;39(21):4155-4169
pubmed: 32269299
Nanomedicine (Lond). 2016 Apr;11(8):881-90
pubmed: 27021928
Thromb Haemost. 2009 Oct;102(4):711-8
pubmed: 19806257
Cytotherapy. 2018 Feb;20(2):181-188
pubmed: 29269240
Front Oncol. 2019 Sep 24;9:965
pubmed: 31681559
Cancer Lett. 2017 May 1;393:86-93
pubmed: 28232049
J Biol Chem. 1997 Apr 11;272(15):10004-12
pubmed: 9092542
Sci Adv. 2019 Nov 20;5(11):eaax8849
pubmed: 31799396
Gastroenterology. 2019 Jan;156(1):108-118.e4
pubmed: 30240661
Neuro Oncol. 2017 Oct 19;19(11):1494-1502
pubmed: 28453784